FKBP5 Mediates Alveolar Fibroblast Necroptosis During Acute Respiratory Distress Syndrome
Cell Proliferation · 2026-01 · 59 (1)
DOI: 10.1111/cpr.70075 ↗At a glance
Journal article in Cell Proliferation, published online on 2025-06-17. Written by Dong Zhang and 9 co-authors. Institution: Department of Intensive Care Unit, Binzhou Medical University Hospital, Binzhou, Shandong, China. Major MEDLINE topics: Tacrolimus Binding Proteins, Respiratory Distress Syndrome, Fibroblasts, Necroptosis. Cited 13 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, Taishan Scholar Project of Shandong Province.
Abstract (original language)
The inflammatory storm is a hallmark of acute respiratory distress syndrome (ARDS), yet effective therapies remain unavailable. FK506‐binding protein 51 (FKBP5) has emerged as a regulator of inflammatory responses. In this study, FKBP5 expression was markedly increased in patients with sepsis and correlated with both cytokine levels and disease severity. Using sepsis‐induced ARDS models in Fkbp5 −/− and bone marrow chimeric mice, this study demonstrated that non‐haematopoietic FKBP5 mitigates inflammatory injury. Single‐cell transcriptomic analysis identified fibroblasts and epithelial cells as the primary sources of non‐haematopoietic FKBP5 in the lung injury. Conditional deletion of FKBP5 in fibroblasts ( Col1a2 ‐iCre Fkbp5 flox/flox ) confirmed the essential role of fibroblast FKBP5 in the inflammatory response during ARDS. Mechanistically, FKBP5‐mediated necroptosis of alveolar fibroblasts triggered NF‐κB activation, proinflammatory cytokine release, neutrophil recruitment, and the establishment of an inflammatory microenvironment in alveolar epithelial tissue. These findings suggest a potential therapeutic strategy targeting fibroblast FKBP5 and provide a foundation for future clinical investigation in ARDS management.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Intensive Care Unit, Binzhou Medical University Hospital, Binzhou, Shandong, China.
- Department of Clinical Laboratory, Binzhou Medical University Hospital, Binzhou, Shandong, China.
- Department of Medical Technology, Binzhou Polytechnic, Binzhou, Shandong, China.
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Jinan, Ch…
- Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.
ORCID profiles: Dong Zhang
Funding
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Natural Science Foundation of China
- Taishan Scholar Project of Shandong Province
- Key Clinical Specialty Project of Shandong Province
- Shandong Province Natural Science Foundation
- Shandong Postdoctoral Science Foundation
- Doctoral Project Foundation of Binzhou Medical University Hospital
- Taishan Scholar Foundation of Shandong Province
Cite
APA
Zhang, D., Liu, W., Sun, T., Xiao, Y., Chen, Q., Huang, X., Wang, X., Qi, Q., Wang, H., & Wang, T. (2026). FKBP5 Mediates Alveolar Fibroblast Necroptosis During Acute Respiratory Distress Syndrome. Cell Proliferation, 59(1). https://doi.org/10.1111/cpr.70075
Vancouver
Zhang D, Liu W, Sun T, Xiao Y, Chen Q, Huang X, et al. FKBP5 Mediates Alveolar Fibroblast Necroptosis During Acute Respiratory Distress Syndrome. Cell Proliferation. 2026;59(1). doi:10.1111/cpr.70075
BibTeX
@article{Zhang2026,
author = {Zhang, Dong and Liu, Wei and Sun, Ting and Xiao, Yangyang and Chen, Qiuwen and Huang, Xiao and Wang, Xiaozhi and Qi, Qian and Wang, Hao and Wang, Tao},
title = {FKBP5 Mediates Alveolar Fibroblast Necroptosis During Acute Respiratory Distress Syndrome},
journal = {Cell Proliferation},
year = {2026},
volume = {59},
number = {1},
doi = {10.1111/cpr.70075}
}
EUVIMED